News

Net profit of Concord Biotech rose 32.84% to Rs 58.53 crore in the quarter ended June 2026 as against Rs 44.06 crore during the previous quarter ended June 2025. Sales rose 26.23% to Rs 257.49 crore in the quarter ended June 2026 as against Rs 203.99 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales257.49203.99 26 OPM %31.9930.10 - PBDT96.4476.51 26 PBT78.3458.73 33 NP58.5344.06 33 Powered by Capital Market - Live News

Concord Biotech will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Concord Biotech announced that the 41th Annual General Meeting(AGM) of the company will be held on 31 July 2026.

Concord Biotech announced the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit-II formulation facility. The inspection took place from 18 June 2026 to 24 June 2026, and was concluded successfully.

Concord Biotech announced the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at the company`s API manufacturing facility in Limbasi. The inspection took place from 08 June to 12 June 2026, and was concluded successfully.